文献速递肝病

HSK31679治疗亚洲MASLD患者的随机对照试验

Efficacy and Safety of HSK31679 in Asian Patients With MASLD: A Randomized Controlled Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-08-20

这项2a期多中心随机双盲安慰剂对照研究在中国26个中心纳入210例肝脂肪含量≥8%的MASLD患者,按1:1:1:1:1随机接受HSK31679 40mg、80mg、160mg、依折麦布10mg或安慰剂治疗12周。主要终点为肝脂肪含量相对变化,80mg和160mg组较安慰剂显著降低,最常见不良事件为腹泻,无药物相关严重不良事件。

要点

  • HSK31679 80mg和160mg治疗12周可显著降低MASLD患者肝脂肪含量。
  • 40mg组肝脂肪含量降低未达统计学显著。
  • 最常见不良事件为腹泻,无药物相关严重不良事件或≥3级不良事件。

核心结论

  • 在亚洲MASLD患者中,HSK31679耐受性良好,80mg和160mg治疗12周后肝脂肪含量显著降低。

研究设计与样本

  • 2a期、多中心、随机、双盲、安慰剂对照研究,在中国26个中心开展。
  • 筛选时磁共振成像质子密度脂肪分数评估肝脂肪含量≥8%的受试者符合条件。
  • 受试者按1:1:1:1:1比例随机接受每日口服HSK31679 40mg、80mg、160mg、依折麦布10mg或安慰剂。
  • 共210例参与者随机分配至安慰剂组(n=42)、HSK31679 40mg组(n=42)、80mg组(n=42)、160mg组(n=42)或依折麦布组(n=42)。
  • 主要终点为治疗12周后肝脂肪含量相对基线的变化。

主要发现

  • 第12周时,安慰剂组肝脂肪含量相对基线平均变化为-4.1%。
  • 最常见治疗中出现的不良事件为腹泻,40mg组11例(26.2%)、80mg组13例(31.0%)、160mg组16例(38.1%)、安慰剂组2例(4.8%)。

临床怎么用

  • 对于亚洲MASLD患者,HSK31679 80mg或160mg每日口服12周可显著降低肝脂肪含量,且耐受性良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: This study evaluated the efficacy and safety of the thyroid hormone receptor β agonist HSK31679 in Asian patients with metabolic dysfunction-associated steatotic liver disease (MASLD). METHODS: This was a phase 2a, multicenter, randomized, double-blind, placebo-controlled study at 26 centers in China. Subjects with a liver fat content (LFC) of ≥8% at screening, when assessed by magnetic resonance imaging-proton density fat fraction, were eligible. Subjects were randomly assigned in a 1:1:1:1:1 ratio using a centralized randomization system to receive daily oral HSK31679 40 mg, HSK31679 80 mg, HSK31679 160 mg, ezetimibe 10 mg, or placebo. The primary endpoint was a relative change from baseline in LFC after 12 weeks of treatment. RESULTS: A total of 210 participants were randomly assigned to placebo (n = 42), HSK31679 40 mg (n = 42), HSK31679 80 mg (n = 42), HSK31679 160 mg (n = 42), or ezetimibe (n = 42). At week 12, the mean relative change from baseline in LFC was -4.1% in the placebo group, -14.0% in the 40 mg group (mean difference vs placebo -9.9% [95% confidence interval (CI), -21.5% to 1.6%]; P = .092), -22.7% in the 80 mg group (-18.6% [95% CI, -30.2% to -7.0%]; P = .002), and -29.2% in the 160 mg group (-25.2% [95% CI, -36.8% to -13.5%]; P < .001). The most common treatment-emergent adverse event was diarrhea (11 [26.2%] of patients in the 40 mg group, 13 [31.0%] in the 80 mg group, 16 [38.1%] in the 160 mg group, and 2 [4.8%] in the placebo group). No drug-related serious adverse events or grade ≥3 adverse events were reported. CONCLUSIONS: In Asian MASLD patients, HSK31679 was well tolerated, with significant reductions in LFC after 12 weeks of treatment with 80 mg and 160 mg. CLINICALTRIALS: gov, Number: NCT05795517.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Xue F, Ma W, Gao J, et al. Efficacy and Safety of HSK31679 in Asian Patients With MASLD: A Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2025. PMID: 40846146. doi:10.1016/j.cgh.2025.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。